Bellicum Pharmaceuticals, Inc BLCM
We take great care to ensure that the data presented and summarized in this overview for BELLICUM PHARMACEUTICALS, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BLCM
Top Purchases
Top Sells
About BLCM
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Insider Transactions at BLCM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Nov 22
2023
|
Baker Bros. Advisors LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,116,349
+47.14%
|
-
|
|
Jan 03
2023
|
Jon P Stonehouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
121,452
+37.31%
|
-
|
|
Jan 03
2023
|
Reid M Huber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
87,196
+36.28%
|
-
|
|
Jan 03
2023
|
Stephen Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
74,739
+35.32%
|
-
|
|
Jan 03
2023
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,414
+35.48%
|
-
|
|
Jan 03
2023
|
Judith V Klimovsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,414
+35.43%
|
-
|
|
Sep 01
2022
|
Judith V Klimovsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
35,082
+41.39%
|
-
|
|
Sep 01
2022
|
Stephen Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
43,400
+41.13%
|
-
|
|
Sep 01
2022
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
35,082
+41.5%
|
-
|
|
Sep 01
2022
|
Reid M Huber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,489
+41.33%
|
-
|
|
Sep 01
2022
|
Jon P Stonehouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,580
+36.88%
|
-
|
|
Jan 04
2022
|
Stephen Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,715
+50.0%
|
-
|
|
Jan 04
2022
|
Judith V Klimovsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,602
+26.87%
|
-
|
|
Jan 04
2022
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,377
+27.66%
|
-
|
|
Jan 04
2022
|
Jon P Stonehouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,504
+48.86%
|
-
|
|
Jan 04
2022
|
James F Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,384
+50.0%
|
-
|
|
Jan 04
2022
|
Reid M Huber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,494
+50.0%
|
-
|
|
Jan 19
2018
|
Baker Bros. Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
295,361
-6.64%
|
$2,067,527
$7.91 P/Share
|
|
Jan 18
2018
|
Baker Bros. Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
324,774
-6.81%
|
$2,598,192
$8.12 P/Share
|
|
Jan 17
2018
|
Baker Bros. Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
260,600
-5.18%
|
$2,084,800
$8.63 P/Share
|